Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases
摘要:
A series of isothiazolopyrimidines and isoxazolopyrimidines were synthesized and identified as potent KDR inhibitors. SAR studies led to isothiazolopyrimidine urea analogs that potently inhibit VEGFR tyrosine kinases (KDR enzymatic and cellular IC50 values below 10 nM) as well as cKIT and TIE2. The selected compounds 8 and 13 display 56% and 48% oral bioavailability in mice, respectively. (c) 2006 Elsevier Ltd. All rights reserved.
Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
申请人:——
公开号:US20040014756A1
公开(公告)日:2004-01-22
Compounds having the formula
1
are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
[EN] THIOPYRIMIDINE AND ISOTHIAZOLOPYRIMIDINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DES THIOPYRIMIDINE ET ISOTHIAZOLOPYRIMIDINE KINASES
申请人:ABBOTT LAB
公开号:WO2003080625A1
公开(公告)日:2003-10-02
Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors
申请人:Michaelides R. Michael
公开号:US20060276490A1
公开(公告)日:2006-12-07
Compounds having the formula
are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.